Gossamer Bio Newsroom

Gossamer Bio Is Maintained at Buy by Goldman Sachs

Dow JonesApr 17 13:49 ET

Gossamer Bio Analyst Ratings

BenzingaApr 17 13:39 ET

H.C. Wainwright Maintains Gossamer Bio(GOSS.US) With Buy Rating, Maintains Target Price $10

Moomoo NewsMar 19 03:32 ET

Gossamer Bio Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow JonesMar 18 06:48 ET

Buy Rating for Gossamer Bio: Seralutinib's Transformative Potential in Pulmonary Hypertension

TipRanksMar 18 06:29 ET

Gossamer Bio Analyst Ratings

BenzingaMar 14 09:45 ET

Piper Sandler Sticks to Their Buy Rating for Gossamer Bio (GOSS)

TipRanksMar 14 07:11 ET

Gossamer Bio Analyst Ratings

BenzingaJan 30 06:43 ET

HC Wainwright & Co. Reiterates Buy on Gossamer Bio, Maintains $10 Price Target

BenzingaJan 30 06:43 ET

Gossamer Bio's Strategic Focus on PAH Unmet Needs and Seralutinib Efficacy Drives Buy Rating

TipRanksJan 27 01:21 ET

Gossamer Bio (GOSS) Gets a Buy From Oppenheimer

TipRanksNov 12, 2024 07:52 ET

HC Wainwright & Co. Reiterates Buy on Gossamer Bio, Maintains $10 Price Target

BenzingaNov 11, 2024 10:11 ET

Gossamer Bio Analyst Ratings

BenzingaNov 11, 2024 10:10 ET

Promising Progress and Expansion Potential of Gossamer Bio's Seralutinib Drive Buy Rating

TipRanksNov 11, 2024 06:23 ET

Oppenheimer Maintains Gossamer Bio(GOSS.US) With Buy Rating, Raises Target Price to $9

Moomoo NewsSep 16, 2024 08:31 ET

Gossamer Bio Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow JonesAug 30, 2024 05:52 ET

Goldman Sachs Maintains Gossamer Bio(GOSS.US) With Buy Rating, Maintains Target Price $8

Moomoo NewsAug 14, 2024 07:31 ET

Buy Rating Affirmed for Gossamer Bio Amidst Financial Growth and Clinical Advancements

TipRanksAug 14, 2024 06:37 ET

Barclays Reaffirms Their Hold Rating on Gossamer Bio (GOSS)

TipRanksAug 14, 2024 03:53 ET

Gossamer Bio Analyst Ratings

BenzingaAug 13, 2024 08:31 ET